Immunology company Immunovant's Q1 net loss widens to $120.6 mln
Overview
Immunovant fiscal Q1 net loss widens to $120.6 mln, driven by higher R&D costs
Company initiated registrational trials for IMVT-1402 in GD and SjD
Cash balance provides runway through GD readout expected in 2027
Outlook
Immunovant expects GD remission data at ATA meeting in September 2025
Company anticipates top-line results for IMVT-1402 trials in 2027
Immunovant has cash runway through GD readout expected in 2027
Company plans to report D2T RA trial results in 2026
Result Drivers
R&D EXPENSES - Increase driven by clinical trial activities and contract manufacturing costs
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Net Income |
| -$120.61 mln |
|
Q1 Basic EPS |
| -$0.71 |
|
Q1 Operating Expenses |
| $127.22 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Immunovant Inc is $44.50, about 65.3% above its August 8 closing price of $15.46
Press Release: ID:nGNX3qzJLz
Related Articles
Investing in Healthcare Stocks
TradingKey - After a year of underperformance, the health care sector is emerging as one of the most interesting places for long-term investors looking for a mixture of resilience and innovation. The health care stocks trailed broader indexes in 2024 as money poured into AI, technology...
Seth Klarman Portfolio
TradingKey - Seth Klarman, the Baupost value investor, long had the distinction of navigating doubt with surgeon-like precision. The technique is married to asymmetric bets, deep margin-of-safety work, and, of course, in many cases, a dash of contrarian genius..jfif)
U.S. Stock Strategy: The Rapid Development of AI Signals a Promising Future
TradingKey - Since Trump announced a 90-day suspension of the "reciprocal tariffs" imposed on certain countries on 9 April this year, all three major U.S. stock indices have recorded significant gains. Looking ahead, against the backdrop of easing global trade frictions.
China July Inflation Commentary: CPI Exceeds Expectations
TradingKey - On 9 August 2025, China's National Bureau of Statistics released inflation data for July. The Consumer Price Index (CPI) rose by 0.4% month-on-month, reversing the previous month's 0.1% decline, while remaining unchanged year-on-year. Core CPI increased by 0.8% year-on-year.
U.S. CPI Preview: Bullish Outlook for U.S. Stocks Continues
TradingKey - On 12 August 2025, the U.S. will release its July CPI data. Market consensus forecasts a year-over-year headline CPI increase of 2.8% and a core CPI rise of 3%, both up 0.1 percentage points from June. We align with these widely held market expectations. Breaking it down by category...
